nodes	percent_of_prediction	percent_of_DWPC	metapath
Ezogabine—NAT2—systemic lupus erythematosus	0.487	1	CbGaD
Ezogabine—NAT2—Dapsone—systemic lupus erythematosus	0.247	0.615	CbGbCtD
Ezogabine—UGT1A9—Mycophenolate mofetil—systemic lupus erythematosus	0.0626	0.156	CbGbCtD
Ezogabine—UGT1A1—Mycophenolate mofetil—systemic lupus erythematosus	0.0512	0.127	CbGbCtD
Ezogabine—CYP2A6—Prednisolone—systemic lupus erythematosus	0.0257	0.064	CbGbCtD
Ezogabine—CYP2A6—Dexamethasone—systemic lupus erythematosus	0.0152	0.0377	CbGbCtD
Ezogabine—NAT2—urine—systemic lupus erythematosus	0.00968	0.292	CbGeAlD
Ezogabine—UGT1A1—urine—systemic lupus erythematosus	0.00358	0.108	CbGeAlD
Ezogabine—UGT1A4—blood plasma—systemic lupus erythematosus	0.00325	0.0983	CbGeAlD
Ezogabine—UGT1A1—blood plasma—systemic lupus erythematosus	0.00187	0.0564	CbGeAlD
Ezogabine—KCNQ4—tendon—systemic lupus erythematosus	0.00162	0.0488	CbGeAlD
Ezogabine—KCNQ5—tendon—systemic lupus erythematosus	0.00157	0.0475	CbGeAlD
Ezogabine—UGT1A4—kidney—systemic lupus erythematosus	0.00147	0.0445	CbGeAlD
Ezogabine—KCNQ5—nervous system—systemic lupus erythematosus	0.00128	0.0386	CbGeAlD
Ezogabine—UGT1A9—kidney—systemic lupus erythematosus	0.00124	0.0373	CbGeAlD
Ezogabine—KCNQ5—central nervous system—systemic lupus erythematosus	0.00123	0.0371	CbGeAlD
Ezogabine—KCNQ3—lung—systemic lupus erythematosus	0.00111	0.0334	CbGeAlD
Ezogabine—UGT1A4—Arylamine metabolism—NAT2—systemic lupus erythematosus	0.00103	0.158	CbGpPWpGaD
Ezogabine—KCNQ3—nervous system—systemic lupus erythematosus	0.00102	0.031	CbGeAlD
Ezogabine—KCNQ3—central nervous system—systemic lupus erythematosus	0.000987	0.0298	CbGeAlD
Ezogabine—KCNQ2—nervous system—systemic lupus erythematosus	0.000943	0.0285	CbGeAlD
Ezogabine—KCNQ2—central nervous system—systemic lupus erythematosus	0.000908	0.0274	CbGeAlD
Ezogabine—UGT1A1—kidney—systemic lupus erythematosus	0.000847	0.0256	CbGeAlD
Ezogabine—UGT1A9—Arylamine metabolism—NAT2—systemic lupus erythematosus	0.000591	0.0908	CbGpPWpGaD
Ezogabine—CYP2A6—lung—systemic lupus erythematosus	0.000506	0.0153	CbGeAlD
Ezogabine—UGT1A4—Constitutive Androstane Receptor Pathway—RXRA—systemic lupus erythematosus	0.000151	0.0232	CbGpPWpGaD
Ezogabine—Leukopenia—Mycophenolate mofetil—systemic lupus erythematosus	0.000151	0.0021	CcSEcCtD
Ezogabine—Feeling abnormal—Leflunomide—systemic lupus erythematosus	0.000151	0.0021	CcSEcCtD
Ezogabine—Hallucination—Betamethasone—systemic lupus erythematosus	0.00015	0.00209	CcSEcCtD
Ezogabine—Hallucination—Dexamethasone—systemic lupus erythematosus	0.00015	0.00209	CcSEcCtD
Ezogabine—Weight increased—Prednisone—systemic lupus erythematosus	0.000149	0.00208	CcSEcCtD
Ezogabine—Vision blurred—Prednisolone—systemic lupus erythematosus	0.000148	0.00207	CcSEcCtD
Ezogabine—Loss of consciousness—Mycophenolate mofetil—systemic lupus erythematosus	0.000148	0.00207	CcSEcCtD
Ezogabine—Anxiety—Cyclosporine—systemic lupus erythematosus	0.000147	0.00204	CcSEcCtD
Ezogabine—Liver function test abnormal—Methotrexate—systemic lupus erythematosus	0.000146	0.00204	CcSEcCtD
Ezogabine—Ill-defined disorder—Prednisolone—systemic lupus erythematosus	0.000146	0.00203	CcSEcCtD
Ezogabine—Discomfort—Cyclosporine—systemic lupus erythematosus	0.000145	0.00203	CcSEcCtD
Ezogabine—Visual impairment—Dexamethasone—systemic lupus erythematosus	0.000145	0.00202	CcSEcCtD
Ezogabine—Visual impairment—Betamethasone—systemic lupus erythematosus	0.000145	0.00202	CcSEcCtD
Ezogabine—Mental disorder—Methylprednisolone—systemic lupus erythematosus	0.000145	0.00202	CcSEcCtD
Ezogabine—Malnutrition—Methylprednisolone—systemic lupus erythematosus	0.000144	0.00201	CcSEcCtD
Ezogabine—Dry mouth—Cyclosporine—systemic lupus erythematosus	0.000144	0.00201	CcSEcCtD
Ezogabine—Anxiety—Mycophenolate mofetil—systemic lupus erythematosus	0.000143	0.00199	CcSEcCtD
Ezogabine—Ill-defined disorder—Hydrocortisone—systemic lupus erythematosus	0.000142	0.00199	CcSEcCtD
Ezogabine—Confusional state—Cyclosporine—systemic lupus erythematosus	0.000142	0.00198	CcSEcCtD
Ezogabine—Malaise—Prednisolone—systemic lupus erythematosus	0.000142	0.00198	CcSEcCtD
Ezogabine—Discomfort—Mycophenolate mofetil—systemic lupus erythematosus	0.000142	0.00198	CcSEcCtD
Ezogabine—Vertigo—Prednisolone—systemic lupus erythematosus	0.000141	0.00197	CcSEcCtD
Ezogabine—Syncope—Prednisolone—systemic lupus erythematosus	0.000141	0.00197	CcSEcCtD
Ezogabine—Eye disorder—Dexamethasone—systemic lupus erythematosus	0.000141	0.00196	CcSEcCtD
Ezogabine—Eye disorder—Betamethasone—systemic lupus erythematosus	0.000141	0.00196	CcSEcCtD
Ezogabine—Dry mouth—Mycophenolate mofetil—systemic lupus erythematosus	0.00014	0.00196	CcSEcCtD
Ezogabine—Infection—Cyclosporine—systemic lupus erythematosus	0.00014	0.00195	CcSEcCtD
Ezogabine—Confusional state—Mycophenolate mofetil—systemic lupus erythematosus	0.000139	0.00193	CcSEcCtD
Ezogabine—Malaise—Hydrocortisone—systemic lupus erythematosus	0.000138	0.00193	CcSEcCtD
Ezogabine—Nervous system disorder—Cyclosporine—systemic lupus erythematosus	0.000138	0.00193	CcSEcCtD
Ezogabine—Loss of consciousness—Prednisolone—systemic lupus erythematosus	0.000138	0.00193	CcSEcCtD
Ezogabine—Thrombocytopenia—Cyclosporine—systemic lupus erythematosus	0.000138	0.00192	CcSEcCtD
Ezogabine—Vertigo—Hydrocortisone—systemic lupus erythematosus	0.000138	0.00192	CcSEcCtD
Ezogabine—Syncope—Hydrocortisone—systemic lupus erythematosus	0.000138	0.00192	CcSEcCtD
Ezogabine—Infection—Mycophenolate mofetil—systemic lupus erythematosus	0.000137	0.00191	CcSEcCtD
Ezogabine—Hyperhidrosis—Cyclosporine—systemic lupus erythematosus	0.000136	0.0019	CcSEcCtD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—IL12B—systemic lupus erythematosus	0.000136	0.0209	CbGpPWpGaD
Ezogabine—Shock—Mycophenolate mofetil—systemic lupus erythematosus	0.000135	0.00189	CcSEcCtD
Ezogabine—Loss of consciousness—Hydrocortisone—systemic lupus erythematosus	0.000135	0.00188	CcSEcCtD
Ezogabine—Nervous system disorder—Mycophenolate mofetil—systemic lupus erythematosus	0.000135	0.00188	CcSEcCtD
Ezogabine—Thrombocytopenia—Mycophenolate mofetil—systemic lupus erythematosus	0.000135	0.00188	CcSEcCtD
Ezogabine—Ill-defined disorder—Triamcinolone—systemic lupus erythematosus	0.000134	0.00187	CcSEcCtD
Ezogabine—Ill-defined disorder—Methylprednisolone—systemic lupus erythematosus	0.000134	0.00187	CcSEcCtD
Ezogabine—Alopecia—Dexamethasone—systemic lupus erythematosus	0.000133	0.00186	CcSEcCtD
Ezogabine—Alopecia—Betamethasone—systemic lupus erythematosus	0.000133	0.00186	CcSEcCtD
Ezogabine—Hyperhidrosis—Mycophenolate mofetil—systemic lupus erythematosus	0.000133	0.00185	CcSEcCtD
Ezogabine—Discomfort—Prednisolone—systemic lupus erythematosus	0.000132	0.00184	CcSEcCtD
Ezogabine—Asthenia—Leflunomide—systemic lupus erythematosus	0.000131	0.00183	CcSEcCtD
Ezogabine—Hallucination—Prednisone—systemic lupus erythematosus	0.000131	0.00182	CcSEcCtD
Ezogabine—Malaise—Triamcinolone—systemic lupus erythematosus	0.00013	0.00182	CcSEcCtD
Ezogabine—Anxiety—Hydrocortisone—systemic lupus erythematosus	0.00013	0.00182	CcSEcCtD
Ezogabine—Malaise—Methylprednisolone—systemic lupus erythematosus	0.00013	0.00181	CcSEcCtD
Ezogabine—Vertigo—Triamcinolone—systemic lupus erythematosus	0.00013	0.00181	CcSEcCtD
Ezogabine—Syncope—Triamcinolone—systemic lupus erythematosus	0.00013	0.00181	CcSEcCtD
Ezogabine—Vertigo—Methylprednisolone—systemic lupus erythematosus	0.00013	0.00181	CcSEcCtD
Ezogabine—Syncope—Methylprednisolone—systemic lupus erythematosus	0.000129	0.0018	CcSEcCtD
Ezogabine—Discomfort—Hydrocortisone—systemic lupus erythematosus	0.000129	0.0018	CcSEcCtD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—JUNB—systemic lupus erythematosus	0.000129	0.0198	CbGpPWpGaD
Ezogabine—Neutropenia—Methotrexate—systemic lupus erythematosus	0.000128	0.00179	CcSEcCtD
Ezogabine—Dysuria—Methotrexate—systemic lupus erythematosus	0.000128	0.00179	CcSEcCtD
Ezogabine—Dizziness—Azathioprine—systemic lupus erythematosus	0.000128	0.00178	CcSEcCtD
Ezogabine—Loss of consciousness—Triamcinolone—systemic lupus erythematosus	0.000127	0.00177	CcSEcCtD
Ezogabine—Loss of consciousness—Methylprednisolone—systemic lupus erythematosus	0.000127	0.00177	CcSEcCtD
Ezogabine—Paraesthesia—Cyclosporine—systemic lupus erythematosus	0.000127	0.00177	CcSEcCtD
Ezogabine—Shock—Prednisolone—systemic lupus erythematosus	0.000126	0.00176	CcSEcCtD
Ezogabine—Dyspnoea—Cyclosporine—systemic lupus erythematosus	0.000126	0.00175	CcSEcCtD
Ezogabine—UGT1A3—Constitutive Androstane Receptor Pathway—RXRA—systemic lupus erythematosus	0.000126	0.0193	CbGpPWpGaD
Ezogabine—Somnolence—Cyclosporine—systemic lupus erythematosus	0.000125	0.00175	CcSEcCtD
Ezogabine—Infection—Hydrocortisone—systemic lupus erythematosus	0.000124	0.00174	CcSEcCtD
Ezogabine—Dyspepsia—Cyclosporine—systemic lupus erythematosus	0.000124	0.00173	CcSEcCtD
Ezogabine—Hyperhidrosis—Prednisolone—systemic lupus erythematosus	0.000124	0.00173	CcSEcCtD
Ezogabine—Paraesthesia—Mycophenolate mofetil—systemic lupus erythematosus	0.000123	0.00172	CcSEcCtD
Ezogabine—Shock—Hydrocortisone—systemic lupus erythematosus	0.000123	0.00172	CcSEcCtD
Ezogabine—Nervous system disorder—Hydrocortisone—systemic lupus erythematosus	0.000123	0.00171	CcSEcCtD
Ezogabine—Eye disorder—Prednisone—systemic lupus erythematosus	0.000123	0.00171	CcSEcCtD
Ezogabine—Dyspnoea—Mycophenolate mofetil—systemic lupus erythematosus	0.000123	0.00171	CcSEcCtD
Ezogabine—Anxiety—Methylprednisolone—systemic lupus erythematosus	0.000122	0.00171	CcSEcCtD
Ezogabine—Somnolence—Mycophenolate mofetil—systemic lupus erythematosus	0.000122	0.0017	CcSEcCtD
Ezogabine—Infestation NOS—Methotrexate—systemic lupus erythematosus	0.000122	0.0017	CcSEcCtD
Ezogabine—Infestation—Methotrexate—systemic lupus erythematosus	0.000122	0.0017	CcSEcCtD
Ezogabine—Rash—Azathioprine—systemic lupus erythematosus	0.000122	0.0017	CcSEcCtD
Ezogabine—Dermatitis—Azathioprine—systemic lupus erythematosus	0.000122	0.0017	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Cyclosporine—systemic lupus erythematosus	0.000122	0.0017	CcSEcCtD
Ezogabine—Ill-defined disorder—Dexamethasone—systemic lupus erythematosus	0.000122	0.0017	CcSEcCtD
Ezogabine—Ill-defined disorder—Betamethasone—systemic lupus erythematosus	0.000122	0.0017	CcSEcCtD
Ezogabine—Discomfort—Triamcinolone—systemic lupus erythematosus	0.000122	0.0017	CcSEcCtD
Ezogabine—Fatigue—Cyclosporine—systemic lupus erythematosus	0.000122	0.00169	CcSEcCtD
Ezogabine—Discomfort—Methylprednisolone—systemic lupus erythematosus	0.000121	0.00169	CcSEcCtD
Ezogabine—Hyperhidrosis—Hydrocortisone—systemic lupus erythematosus	0.000121	0.00169	CcSEcCtD
Ezogabine—Dyspepsia—Mycophenolate mofetil—systemic lupus erythematosus	0.000121	0.00169	CcSEcCtD
Ezogabine—Dizziness—Leflunomide—systemic lupus erythematosus	0.000121	0.00168	CcSEcCtD
Ezogabine—Constipation—Cyclosporine—systemic lupus erythematosus	0.000121	0.00168	CcSEcCtD
Ezogabine—Dry mouth—Triamcinolone—systemic lupus erythematosus	0.00012	0.00168	CcSEcCtD
Ezogabine—UGT1A4—Phase II conjugation—NAT2—systemic lupus erythematosus	0.00012	0.0184	CbGpPWpGaD
Ezogabine—Gastrointestinal disorder—Mycophenolate mofetil—systemic lupus erythematosus	0.000119	0.00166	CcSEcCtD
Ezogabine—Confusional state—Methylprednisolone—systemic lupus erythematosus	0.000119	0.00166	CcSEcCtD
Ezogabine—Malaise—Betamethasone—systemic lupus erythematosus	0.000118	0.00165	CcSEcCtD
Ezogabine—Malaise—Dexamethasone—systemic lupus erythematosus	0.000118	0.00165	CcSEcCtD
Ezogabine—Vertigo—Betamethasone—systemic lupus erythematosus	0.000118	0.00164	CcSEcCtD
Ezogabine—Vertigo—Dexamethasone—systemic lupus erythematosus	0.000118	0.00164	CcSEcCtD
Ezogabine—Syncope—Dexamethasone—systemic lupus erythematosus	0.000118	0.00164	CcSEcCtD
Ezogabine—Syncope—Betamethasone—systemic lupus erythematosus	0.000118	0.00164	CcSEcCtD
Ezogabine—Constipation—Mycophenolate mofetil—systemic lupus erythematosus	0.000118	0.00164	CcSEcCtD
Ezogabine—Infection—Triamcinolone—systemic lupus erythematosus	0.000117	0.00163	CcSEcCtD
Ezogabine—Infection—Methylprednisolone—systemic lupus erythematosus	0.000117	0.00163	CcSEcCtD
Ezogabine—Haematuria—Methotrexate—systemic lupus erythematosus	0.000116	0.00162	CcSEcCtD
Ezogabine—Feeling abnormal—Cyclosporine—systemic lupus erythematosus	0.000116	0.00162	CcSEcCtD
Ezogabine—Shock—Triamcinolone—systemic lupus erythematosus	0.000116	0.00162	CcSEcCtD
Ezogabine—Alopecia—Prednisone—systemic lupus erythematosus	0.000116	0.00162	CcSEcCtD
Ezogabine—Shock—Methylprednisolone—systemic lupus erythematosus	0.000116	0.00161	CcSEcCtD
Ezogabine—Hepatobiliary disease—Methotrexate—systemic lupus erythematosus	0.000116	0.00161	CcSEcCtD
Ezogabine—Nervous system disorder—Methylprednisolone—systemic lupus erythematosus	0.000115	0.00161	CcSEcCtD
Ezogabine—Loss of consciousness—Betamethasone—systemic lupus erythematosus	0.000115	0.00161	CcSEcCtD
Ezogabine—Loss of consciousness—Dexamethasone—systemic lupus erythematosus	0.000115	0.00161	CcSEcCtD
Ezogabine—Paraesthesia—Prednisolone—systemic lupus erythematosus	0.000115	0.00161	CcSEcCtD
Ezogabine—Rash—Leflunomide—systemic lupus erythematosus	0.000115	0.00161	CcSEcCtD
Ezogabine—Dermatitis—Leflunomide—systemic lupus erythematosus	0.000115	0.0016	CcSEcCtD
Ezogabine—Mental disorder—Prednisone—systemic lupus erythematosus	0.000115	0.0016	CcSEcCtD
Ezogabine—Nausea—Azathioprine—systemic lupus erythematosus	0.000115	0.0016	CcSEcCtD
Ezogabine—Malnutrition—Prednisone—systemic lupus erythematosus	0.000114	0.00159	CcSEcCtD
Ezogabine—Hyperhidrosis—Triamcinolone—systemic lupus erythematosus	0.000114	0.00159	CcSEcCtD
Ezogabine—Hyperhidrosis—Methylprednisolone—systemic lupus erythematosus	0.000114	0.00159	CcSEcCtD
Ezogabine—Feeling abnormal—Mycophenolate mofetil—systemic lupus erythematosus	0.000113	0.00158	CcSEcCtD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—IL12B—systemic lupus erythematosus	0.000113	0.0174	CbGpPWpGaD
Ezogabine—Paraesthesia—Hydrocortisone—systemic lupus erythematosus	0.000113	0.00157	CcSEcCtD
Ezogabine—Anxiety—Betamethasone—systemic lupus erythematosus	0.000111	0.00155	CcSEcCtD
Ezogabine—Anxiety—Dexamethasone—systemic lupus erythematosus	0.000111	0.00155	CcSEcCtD
Ezogabine—Discomfort—Dexamethasone—systemic lupus erythematosus	0.00011	0.00154	CcSEcCtD
Ezogabine—Discomfort—Betamethasone—systemic lupus erythematosus	0.00011	0.00154	CcSEcCtD
Ezogabine—Dyspepsia—Hydrocortisone—systemic lupus erythematosus	0.00011	0.00154	CcSEcCtD
Ezogabine—Nausea—Leflunomide—systemic lupus erythematosus	0.000109	0.00151	CcSEcCtD
Ezogabine—Urinary tract disorder—Methotrexate—systemic lupus erythematosus	0.000108	0.00151	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Hydrocortisone—systemic lupus erythematosus	0.000108	0.00151	CcSEcCtD
Ezogabine—Fatigue—Hydrocortisone—systemic lupus erythematosus	0.000108	0.00151	CcSEcCtD
Ezogabine—Vision blurred—Prednisone—systemic lupus erythematosus	0.000108	0.0015	CcSEcCtD
Ezogabine—Urethral disorder—Methotrexate—systemic lupus erythematosus	0.000108	0.0015	CcSEcCtD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—JUNB—systemic lupus erythematosus	0.000107	0.0165	CbGpPWpGaD
Ezogabine—Infection—Betamethasone—systemic lupus erythematosus	0.000106	0.00148	CcSEcCtD
Ezogabine—Infection—Dexamethasone—systemic lupus erythematosus	0.000106	0.00148	CcSEcCtD
Ezogabine—Ill-defined disorder—Prednisone—systemic lupus erythematosus	0.000106	0.00148	CcSEcCtD
Ezogabine—Paraesthesia—Triamcinolone—systemic lupus erythematosus	0.000106	0.00148	CcSEcCtD
Ezogabine—Feeling abnormal—Prednisolone—systemic lupus erythematosus	0.000106	0.00147	CcSEcCtD
Ezogabine—Paraesthesia—Methylprednisolone—systemic lupus erythematosus	0.000106	0.00147	CcSEcCtD
Ezogabine—Visual impairment—Methotrexate—systemic lupus erythematosus	0.000106	0.00147	CcSEcCtD
Ezogabine—Shock—Betamethasone—systemic lupus erythematosus	0.000105	0.00147	CcSEcCtD
Ezogabine—Shock—Dexamethasone—systemic lupus erythematosus	0.000105	0.00147	CcSEcCtD
Ezogabine—Dyspnoea—Triamcinolone—systemic lupus erythematosus	0.000105	0.00147	CcSEcCtD
Ezogabine—Nervous system disorder—Dexamethasone—systemic lupus erythematosus	0.000105	0.00146	CcSEcCtD
Ezogabine—Nervous system disorder—Betamethasone—systemic lupus erythematosus	0.000105	0.00146	CcSEcCtD
Ezogabine—Thrombocytopenia—Dexamethasone—systemic lupus erythematosus	0.000105	0.00146	CcSEcCtD
Ezogabine—Thrombocytopenia—Betamethasone—systemic lupus erythematosus	0.000105	0.00146	CcSEcCtD
Ezogabine—Dyspepsia—Triamcinolone—systemic lupus erythematosus	0.000104	0.00145	CcSEcCtD
Ezogabine—Dyspepsia—Methylprednisolone—systemic lupus erythematosus	0.000104	0.00144	CcSEcCtD
Ezogabine—Hyperhidrosis—Betamethasone—systemic lupus erythematosus	0.000103	0.00144	CcSEcCtD
Ezogabine—Hyperhidrosis—Dexamethasone—systemic lupus erythematosus	0.000103	0.00144	CcSEcCtD
Ezogabine—Feeling abnormal—Hydrocortisone—systemic lupus erythematosus	0.000103	0.00144	CcSEcCtD
Ezogabine—Malaise—Prednisone—systemic lupus erythematosus	0.000103	0.00144	CcSEcCtD
Ezogabine—Vertigo—Prednisone—systemic lupus erythematosus	0.000103	0.00143	CcSEcCtD
Ezogabine—UGT1A9—PPAR Alpha Pathway—RXRA—systemic lupus erythematosus	0.000103	0.0158	CbGpPWpGaD
Ezogabine—Eye disorder—Methotrexate—systemic lupus erythematosus	0.000102	0.00143	CcSEcCtD
Ezogabine—Syncope—Prednisone—systemic lupus erythematosus	0.000102	0.00143	CcSEcCtD
Ezogabine—Fatigue—Triamcinolone—systemic lupus erythematosus	0.000102	0.00142	CcSEcCtD
Ezogabine—Fatigue—Methylprednisolone—systemic lupus erythematosus	0.000101	0.00142	CcSEcCtD
Ezogabine—Asthenia—Cyclosporine—systemic lupus erythematosus	0.000101	0.00141	CcSEcCtD
Ezogabine—Loss of consciousness—Prednisone—systemic lupus erythematosus	0.0001	0.0014	CcSEcCtD
Ezogabine—UGT1A3—Phase II conjugation—NAT2—systemic lupus erythematosus	9.98e-05	0.0153	CbGpPWpGaD
Ezogabine—Asthenia—Mycophenolate mofetil—systemic lupus erythematosus	9.87e-05	0.00138	CcSEcCtD
Ezogabine—Feeling abnormal—Triamcinolone—systemic lupus erythematosus	9.72e-05	0.00136	CcSEcCtD
Ezogabine—Feeling abnormal—Methylprednisolone—systemic lupus erythematosus	9.7e-05	0.00135	CcSEcCtD
Ezogabine—Anxiety—Prednisone—systemic lupus erythematosus	9.69e-05	0.00135	CcSEcCtD
Ezogabine—Alopecia—Methotrexate—systemic lupus erythematosus	9.69e-05	0.00135	CcSEcCtD
Ezogabine—Paraesthesia—Dexamethasone—systemic lupus erythematosus	9.61e-05	0.00134	CcSEcCtD
Ezogabine—Paraesthesia—Betamethasone—systemic lupus erythematosus	9.61e-05	0.00134	CcSEcCtD
Ezogabine—Discomfort—Prednisone—systemic lupus erythematosus	9.61e-05	0.00134	CcSEcCtD
Ezogabine—Mental disorder—Methotrexate—systemic lupus erythematosus	9.61e-05	0.00134	CcSEcCtD
Ezogabine—Malnutrition—Methotrexate—systemic lupus erythematosus	9.55e-05	0.00133	CcSEcCtD
Ezogabine—Dyspepsia—Betamethasone—systemic lupus erythematosus	9.42e-05	0.00131	CcSEcCtD
Ezogabine—Dyspepsia—Dexamethasone—systemic lupus erythematosus	9.42e-05	0.00131	CcSEcCtD
Ezogabine—Dizziness—Cyclosporine—systemic lupus erythematosus	9.32e-05	0.0013	CcSEcCtD
Ezogabine—Infection—Prednisone—systemic lupus erythematosus	9.26e-05	0.00129	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Betamethasone—systemic lupus erythematosus	9.24e-05	0.00129	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Dexamethasone—systemic lupus erythematosus	9.24e-05	0.00129	CcSEcCtD
Ezogabine—Fatigue—Dexamethasone—systemic lupus erythematosus	9.23e-05	0.00129	CcSEcCtD
Ezogabine—Fatigue—Betamethasone—systemic lupus erythematosus	9.23e-05	0.00129	CcSEcCtD
Ezogabine—Shock—Prednisone—systemic lupus erythematosus	9.17e-05	0.00128	CcSEcCtD
Ezogabine—Nervous system disorder—Prednisone—systemic lupus erythematosus	9.14e-05	0.00127	CcSEcCtD
Ezogabine—Dizziness—Mycophenolate mofetil—systemic lupus erythematosus	9.09e-05	0.00127	CcSEcCtD
Ezogabine—Hyperhidrosis—Prednisone—systemic lupus erythematosus	9.01e-05	0.00126	CcSEcCtD
Ezogabine—Vision blurred—Methotrexate—systemic lupus erythematosus	9e-05	0.00125	CcSEcCtD
Ezogabine—Asthenia—Hydrocortisone—systemic lupus erythematosus	8.99e-05	0.00125	CcSEcCtD
Ezogabine—Rash—Cyclosporine—systemic lupus erythematosus	8.89e-05	0.00124	CcSEcCtD
Ezogabine—Dermatitis—Cyclosporine—systemic lupus erythematosus	8.88e-05	0.00124	CcSEcCtD
Ezogabine—Ill-defined disorder—Methotrexate—systemic lupus erythematosus	8.86e-05	0.00124	CcSEcCtD
Ezogabine—Feeling abnormal—Dexamethasone—systemic lupus erythematosus	8.82e-05	0.00123	CcSEcCtD
Ezogabine—Feeling abnormal—Betamethasone—systemic lupus erythematosus	8.82e-05	0.00123	CcSEcCtD
Ezogabine—UGT1A1—Constitutive Androstane Receptor Pathway—RXRA—systemic lupus erythematosus	8.68e-05	0.0133	CbGpPWpGaD
Ezogabine—UGT1A9—Constitutive Androstane Receptor Pathway—RXRA—systemic lupus erythematosus	8.68e-05	0.0133	CbGpPWpGaD
Ezogabine—Rash—Mycophenolate mofetil—systemic lupus erythematosus	8.67e-05	0.00121	CcSEcCtD
Ezogabine—Dermatitis—Mycophenolate mofetil—systemic lupus erythematosus	8.66e-05	0.00121	CcSEcCtD
Ezogabine—Malaise—Methotrexate—systemic lupus erythematosus	8.61e-05	0.0012	CcSEcCtD
Ezogabine—Vertigo—Methotrexate—systemic lupus erythematosus	8.58e-05	0.0012	CcSEcCtD
Ezogabine—Leukopenia—Methotrexate—systemic lupus erythematosus	8.55e-05	0.00119	CcSEcCtD
Ezogabine—Dizziness—Prednisolone—systemic lupus erythematosus	8.48e-05	0.00118	CcSEcCtD
Ezogabine—Asthenia—Triamcinolone—systemic lupus erythematosus	8.46e-05	0.00118	CcSEcCtD
Ezogabine—Asthenia—Methylprednisolone—systemic lupus erythematosus	8.45e-05	0.00118	CcSEcCtD
Ezogabine—Nausea—Cyclosporine—systemic lupus erythematosus	8.37e-05	0.00117	CcSEcCtD
Ezogabine—Paraesthesia—Prednisone—systemic lupus erythematosus	8.37e-05	0.00117	CcSEcCtD
Ezogabine—Dizziness—Hydrocortisone—systemic lupus erythematosus	8.29e-05	0.00116	CcSEcCtD
Ezogabine—Dyspepsia—Prednisone—systemic lupus erythematosus	8.21e-05	0.00114	CcSEcCtD
Ezogabine—Nausea—Mycophenolate mofetil—systemic lupus erythematosus	8.17e-05	0.00114	CcSEcCtD
Ezogabine—Rash—Prednisolone—systemic lupus erythematosus	8.09e-05	0.00113	CcSEcCtD
Ezogabine—Dermatitis—Prednisolone—systemic lupus erythematosus	8.08e-05	0.00113	CcSEcCtD
Ezogabine—Fatigue—Prednisone—systemic lupus erythematosus	8.04e-05	0.00112	CcSEcCtD
Ezogabine—Discomfort—Methotrexate—systemic lupus erythematosus	8.03e-05	0.00112	CcSEcCtD
Ezogabine—Constipation—Prednisone—systemic lupus erythematosus	7.97e-05	0.00111	CcSEcCtD
Ezogabine—Rash—Hydrocortisone—systemic lupus erythematosus	7.9e-05	0.0011	CcSEcCtD
Ezogabine—Dermatitis—Hydrocortisone—systemic lupus erythematosus	7.89e-05	0.0011	CcSEcCtD
Ezogabine—Confusional state—Methotrexate—systemic lupus erythematosus	7.86e-05	0.0011	CcSEcCtD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—systemic lupus erythematosus	7.83e-05	0.012	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL12B—systemic lupus erythematosus	7.83e-05	0.012	CbGpPWpGaD
Ezogabine—Dizziness—Triamcinolone—systemic lupus erythematosus	7.8e-05	0.00109	CcSEcCtD
Ezogabine—Dizziness—Methylprednisolone—systemic lupus erythematosus	7.78e-05	0.00109	CcSEcCtD
Ezogabine—Infection—Methotrexate—systemic lupus erythematosus	7.74e-05	0.00108	CcSEcCtD
Ezogabine—Feeling abnormal—Prednisone—systemic lupus erythematosus	7.68e-05	0.00107	CcSEcCtD
Ezogabine—Asthenia—Dexamethasone—systemic lupus erythematosus	7.68e-05	0.00107	CcSEcCtD
Ezogabine—Asthenia—Betamethasone—systemic lupus erythematosus	7.68e-05	0.00107	CcSEcCtD
Ezogabine—Nervous system disorder—Methotrexate—systemic lupus erythematosus	7.64e-05	0.00107	CcSEcCtD
Ezogabine—Thrombocytopenia—Methotrexate—systemic lupus erythematosus	7.63e-05	0.00106	CcSEcCtD
Ezogabine—Nausea—Prednisolone—systemic lupus erythematosus	7.62e-05	0.00106	CcSEcCtD
Ezogabine—Hyperhidrosis—Methotrexate—systemic lupus erythematosus	7.53e-05	0.00105	CcSEcCtD
Ezogabine—Nausea—Hydrocortisone—systemic lupus erythematosus	7.44e-05	0.00104	CcSEcCtD
Ezogabine—Rash—Triamcinolone—systemic lupus erythematosus	7.44e-05	0.00104	CcSEcCtD
Ezogabine—Dermatitis—Triamcinolone—systemic lupus erythematosus	7.43e-05	0.00104	CcSEcCtD
Ezogabine—Rash—Methylprednisolone—systemic lupus erythematosus	7.42e-05	0.00103	CcSEcCtD
Ezogabine—Dermatitis—Methylprednisolone—systemic lupus erythematosus	7.42e-05	0.00103	CcSEcCtD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—JUNB—systemic lupus erythematosus	7.41e-05	0.0114	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—JUNB—systemic lupus erythematosus	7.41e-05	0.0114	CbGpPWpGaD
Ezogabine—Dizziness—Dexamethasone—systemic lupus erythematosus	7.08e-05	0.000987	CcSEcCtD
Ezogabine—Dizziness—Betamethasone—systemic lupus erythematosus	7.08e-05	0.000987	CcSEcCtD
Ezogabine—UGT1A4—Biological oxidations—NAT2—systemic lupus erythematosus	7.02e-05	0.0108	CbGpPWpGaD
Ezogabine—Nausea—Triamcinolone—systemic lupus erythematosus	7.01e-05	0.000977	CcSEcCtD
Ezogabine—Paraesthesia—Methotrexate—systemic lupus erythematosus	7e-05	0.000975	CcSEcCtD
Ezogabine—Nausea—Methylprednisolone—systemic lupus erythematosus	6.99e-05	0.000975	CcSEcCtD
Ezogabine—Dyspnoea—Methotrexate—systemic lupus erythematosus	6.95e-05	0.000969	CcSEcCtD
Ezogabine—UGT1A4—Metapathway biotransformation—NAT2—systemic lupus erythematosus	6.93e-05	0.0106	CbGpPWpGaD
Ezogabine—Somnolence—Methotrexate—systemic lupus erythematosus	6.93e-05	0.000966	CcSEcCtD
Ezogabine—UGT1A9—Phase II conjugation—NAT2—systemic lupus erythematosus	6.9e-05	0.0106	CbGpPWpGaD
Ezogabine—UGT1A1—Phase II conjugation—NAT2—systemic lupus erythematosus	6.9e-05	0.0106	CbGpPWpGaD
Ezogabine—Dyspepsia—Methotrexate—systemic lupus erythematosus	6.86e-05	0.000956	CcSEcCtD
Ezogabine—Rash—Dexamethasone—systemic lupus erythematosus	6.75e-05	0.000941	CcSEcCtD
Ezogabine—Rash—Betamethasone—systemic lupus erythematosus	6.75e-05	0.000941	CcSEcCtD
Ezogabine—Dermatitis—Betamethasone—systemic lupus erythematosus	6.74e-05	0.00094	CcSEcCtD
Ezogabine—Dermatitis—Dexamethasone—systemic lupus erythematosus	6.74e-05	0.00094	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Methotrexate—systemic lupus erythematosus	6.73e-05	0.000938	CcSEcCtD
Ezogabine—Fatigue—Methotrexate—systemic lupus erythematosus	6.72e-05	0.000937	CcSEcCtD
Ezogabine—CYP2A6—Constitutive Androstane Receptor Pathway—RXRA—systemic lupus erythematosus	6.69e-05	0.0103	CbGpPWpGaD
Ezogabine—Asthenia—Prednisone—systemic lupus erythematosus	6.69e-05	0.000933	CcSEcCtD
Ezogabine—NAT2—Biological oxidations—RXRA—systemic lupus erythematosus	6.5e-05	0.00999	CbGpPWpGaD
Ezogabine—Feeling abnormal—Methotrexate—systemic lupus erythematosus	6.42e-05	0.000895	CcSEcCtD
Ezogabine—Nausea—Betamethasone—systemic lupus erythematosus	6.36e-05	0.000887	CcSEcCtD
Ezogabine—Nausea—Dexamethasone—systemic lupus erythematosus	6.36e-05	0.000887	CcSEcCtD
Ezogabine—Dizziness—Prednisone—systemic lupus erythematosus	6.16e-05	0.00086	CcSEcCtD
Ezogabine—Rash—Prednisone—systemic lupus erythematosus	5.88e-05	0.00082	CcSEcCtD
Ezogabine—Dermatitis—Prednisone—systemic lupus erythematosus	5.87e-05	0.000819	CcSEcCtD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—IFNG—systemic lupus erythematosus	5.86e-05	0.009	CbGpPWpGaD
Ezogabine—UGT1A3—Biological oxidations—NAT2—systemic lupus erythematosus	5.84e-05	0.00897	CbGpPWpGaD
Ezogabine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—PTGS2—systemic lupus erythematosus	5.79e-05	0.00889	CbGpPWpGaD
Ezogabine—UGT1A3—Metapathway biotransformation—NAT2—systemic lupus erythematosus	5.76e-05	0.00885	CbGpPWpGaD
Ezogabine—Asthenia—Methotrexate—systemic lupus erythematosus	5.59e-05	0.000779	CcSEcCtD
Ezogabine—Nausea—Prednisone—systemic lupus erythematosus	5.54e-05	0.000772	CcSEcCtD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—CDKN1B—systemic lupus erythematosus	5.32e-05	0.00817	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—LYN—systemic lupus erythematosus	5.32e-05	0.00817	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—LYN—systemic lupus erythematosus	5.32e-05	0.00817	CbGpPWpGaD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—IL2—systemic lupus erythematosus	5.21e-05	0.008	CbGpPWpGaD
Ezogabine—Dizziness—Methotrexate—systemic lupus erythematosus	5.15e-05	0.000718	CcSEcCtD
Ezogabine—Rash—Methotrexate—systemic lupus erythematosus	4.91e-05	0.000685	CcSEcCtD
Ezogabine—Dermatitis—Methotrexate—systemic lupus erythematosus	4.91e-05	0.000684	CcSEcCtD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—IFNG—systemic lupus erythematosus	4.87e-05	0.00748	CbGpPWpGaD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—EP300—systemic lupus erythematosus	4.67e-05	0.00718	CbGpPWpGaD
Ezogabine—Nausea—Methotrexate—systemic lupus erythematosus	4.63e-05	0.000645	CcSEcCtD
Ezogabine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—systemic lupus erythematosus	4.56e-05	0.00701	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—PTPRC—systemic lupus erythematosus	4.55e-05	0.00699	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—PTPRC—systemic lupus erythematosus	4.55e-05	0.00699	CbGpPWpGaD
Ezogabine—UGT1A4—NRF2 pathway—RXRA—systemic lupus erythematosus	4.49e-05	0.0069	CbGpPWpGaD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—CDKN1B—systemic lupus erythematosus	4.42e-05	0.0068	CbGpPWpGaD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—IL2—systemic lupus erythematosus	4.33e-05	0.00665	CbGpPWpGaD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic lupus erythematosus	4.06e-05	0.00624	CbGpPWpGaD
Ezogabine—CYP2A6—Cytochrome P450 - arranged by substrate type—RXRA—systemic lupus erythematosus	4.05e-05	0.00622	CbGpPWpGaD
Ezogabine—UGT1A1—Biological oxidations—NAT2—systemic lupus erythematosus	4.03e-05	0.0062	CbGpPWpGaD
Ezogabine—UGT1A9—Biological oxidations—NAT2—systemic lupus erythematosus	4.03e-05	0.0062	CbGpPWpGaD
Ezogabine—UGT1A1—Metapathway biotransformation—NAT2—systemic lupus erythematosus	3.98e-05	0.00611	CbGpPWpGaD
Ezogabine—UGT1A9—Metapathway biotransformation—NAT2—systemic lupus erythematosus	3.98e-05	0.00611	CbGpPWpGaD
Ezogabine—UGT1A4—Biological oxidations—RXRA—systemic lupus erythematosus	3.94e-05	0.00605	CbGpPWpGaD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—EP300—systemic lupus erythematosus	3.88e-05	0.00597	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—LYN—systemic lupus erythematosus	3.8e-05	0.00583	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—LYN—systemic lupus erythematosus	3.8e-05	0.00583	CbGpPWpGaD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—TNF—systemic lupus erythematosus	3.79e-05	0.00583	CbGpPWpGaD
Ezogabine—UGT1A3—NRF2 pathway—RXRA—systemic lupus erythematosus	3.73e-05	0.00573	CbGpPWpGaD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic lupus erythematosus	3.38e-05	0.00519	CbGpPWpGaD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—systemic lupus erythematosus	3.37e-05	0.00517	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IFNG—systemic lupus erythematosus	3.37e-05	0.00517	CbGpPWpGaD
Ezogabine—CYP2A6—Phase 1 - Functionalization of compounds—RXRA—systemic lupus erythematosus	3.28e-05	0.00504	CbGpPWpGaD
Ezogabine—UGT1A3—Biological oxidations—RXRA—systemic lupus erythematosus	3.27e-05	0.00503	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—PTPRC—systemic lupus erythematosus	3.25e-05	0.00499	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—PTPRC—systemic lupus erythematosus	3.25e-05	0.00499	CbGpPWpGaD
Ezogabine—UGT1A9—PPARA activates gene expression—RXRA—systemic lupus erythematosus	3.23e-05	0.00497	CbGpPWpGaD
Ezogabine—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—RXRA—systemic lupus erythematosus	3.16e-05	0.00486	CbGpPWpGaD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—TNF—systemic lupus erythematosus	3.15e-05	0.00484	CbGpPWpGaD
Ezogabine—CYP2A6—Biological oxidations—NAT2—systemic lupus erythematosus	3.11e-05	0.00478	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—JAK1—systemic lupus erythematosus	3.1e-05	0.00476	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—JAK1—systemic lupus erythematosus	3.1e-05	0.00476	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—ADIPOQ—systemic lupus erythematosus	3.07e-05	0.00471	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—ADIPOQ—systemic lupus erythematosus	3.07e-05	0.00471	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—CDKN1B—systemic lupus erythematosus	3.06e-05	0.0047	CbGpPWpGaD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—CDKN1B—systemic lupus erythematosus	3.06e-05	0.0047	CbGpPWpGaD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL2—systemic lupus erythematosus	2.99e-05	0.00459	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL2—systemic lupus erythematosus	2.99e-05	0.00459	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EP300—systemic lupus erythematosus	2.68e-05	0.00412	CbGpPWpGaD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EP300—systemic lupus erythematosus	2.68e-05	0.00412	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—RXRA—systemic lupus erythematosus	2.63e-05	0.00404	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—RXRA—systemic lupus erythematosus	2.63e-05	0.00404	CbGpPWpGaD
Ezogabine—UGT1A1—NRF2 pathway—RXRA—systemic lupus erythematosus	2.58e-05	0.00396	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—RXRA—systemic lupus erythematosus	2.58e-05	0.00396	CbGpPWpGaD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic lupus erythematosus	2.33e-05	0.00358	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic lupus erythematosus	2.33e-05	0.00358	CbGpPWpGaD
Ezogabine—UGT1A1—Biological oxidations—RXRA—systemic lupus erythematosus	2.26e-05	0.00347	CbGpPWpGaD
Ezogabine—UGT1A9—Biological oxidations—RXRA—systemic lupus erythematosus	2.26e-05	0.00347	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—JAK1—systemic lupus erythematosus	2.21e-05	0.00339	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—JAK1—systemic lupus erythematosus	2.21e-05	0.00339	CbGpPWpGaD
Ezogabine—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—RXRA—systemic lupus erythematosus	2.18e-05	0.00335	CbGpPWpGaD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—systemic lupus erythematosus	2.18e-05	0.00335	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—systemic lupus erythematosus	2.18e-05	0.00335	CbGpPWpGaD
Ezogabine—UGT1A9—PPARA activates gene expression—PPARG—systemic lupus erythematosus	2.04e-05	0.00314	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—TYK2—systemic lupus erythematosus	2.04e-05	0.00313	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—TYK2—systemic lupus erythematosus	2.04e-05	0.00313	CbGpPWpGaD
Ezogabine—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—systemic lupus erythematosus	2e-05	0.00307	CbGpPWpGaD
Ezogabine—CYP2A6—NRF2 pathway—RXRA—systemic lupus erythematosus	1.99e-05	0.00305	CbGpPWpGaD
Ezogabine—CYP2A6—Biological oxidations—RXRA—systemic lupus erythematosus	1.74e-05	0.00268	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—PPARG—systemic lupus erythematosus	1.66e-05	0.00255	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—PPARG—systemic lupus erythematosus	1.66e-05	0.00255	CbGpPWpGaD
Ezogabine—UGT1A4—NRF2 pathway—TGFB1—systemic lupus erythematosus	1.61e-05	0.00248	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—MMP9—systemic lupus erythematosus	1.6e-05	0.00246	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—MMP9—systemic lupus erythematosus	1.6e-05	0.00246	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—TYK2—systemic lupus erythematosus	1.45e-05	0.00223	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—TYK2—systemic lupus erythematosus	1.45e-05	0.00223	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—VEGFA—systemic lupus erythematosus	1.44e-05	0.00221	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—VEGFA—systemic lupus erythematosus	1.44e-05	0.00221	CbGpPWpGaD
Ezogabine—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—systemic lupus erythematosus	1.38e-05	0.00212	CbGpPWpGaD
Ezogabine—UGT1A3—NRF2 pathway—TGFB1—systemic lupus erythematosus	1.34e-05	0.00206	CbGpPWpGaD
Ezogabine—UGT1A9—PPARA activates gene expression—EP300—systemic lupus erythematosus	1.34e-05	0.00205	CbGpPWpGaD
Ezogabine—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—systemic lupus erythematosus	1.31e-05	0.00201	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—NAT2—systemic lupus erythematosus	1.2e-05	0.00185	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—MMP9—systemic lupus erythematosus	1.14e-05	0.00176	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—MMP9—systemic lupus erythematosus	1.14e-05	0.00176	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—RXRA—systemic lupus erythematosus	1.11e-05	0.00171	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—EP300—systemic lupus erythematosus	1.09e-05	0.00167	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—EP300—systemic lupus erythematosus	1.09e-05	0.00167	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—VEGFA—systemic lupus erythematosus	1.03e-05	0.00158	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—VEGFA—systemic lupus erythematosus	1.03e-05	0.00158	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—NAT2—systemic lupus erythematosus	9.99e-06	0.00153	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—IL6—systemic lupus erythematosus	9.96e-06	0.00153	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—IL6—systemic lupus erythematosus	9.96e-06	0.00153	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—TGFB1—systemic lupus erythematosus	9.43e-06	0.00145	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—TGFB1—systemic lupus erythematosus	9.43e-06	0.00145	CbGpPWpGaD
Ezogabine—UGT1A1—NRF2 pathway—TGFB1—systemic lupus erythematosus	9.26e-06	0.00142	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—TGFB1—systemic lupus erythematosus	9.26e-06	0.00142	CbGpPWpGaD
Ezogabine—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—systemic lupus erythematosus	9.01e-06	0.00138	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—TNF—systemic lupus erythematosus	8.81e-06	0.00135	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—TNF—systemic lupus erythematosus	8.81e-06	0.00135	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—RXRA—systemic lupus erythematosus	8.68e-06	0.00133	CbGpPWpGaD
Ezogabine—CYP2A6—NRF2 pathway—TGFB1—systemic lupus erythematosus	7.14e-06	0.0011	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—IL6—systemic lupus erythematosus	7.11e-06	0.00109	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—IL6—systemic lupus erythematosus	7.11e-06	0.00109	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PPARG—systemic lupus erythematosus	7.02e-06	0.00108	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—NAT2—systemic lupus erythematosus	6.9e-06	0.00106	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—NAT2—systemic lupus erythematosus	6.9e-06	0.00106	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—RXRA—systemic lupus erythematosus	6.73e-06	0.00103	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—ALB—systemic lupus erythematosus	6.31e-06	0.00097	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—NOS3—systemic lupus erythematosus	6.04e-06	0.000927	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—RXRA—systemic lupus erythematosus	5.6e-06	0.00086	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PTGS2—systemic lupus erythematosus	5.52e-06	0.000848	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	5.48e-06	0.000843	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—NAT2—systemic lupus erythematosus	5.32e-06	0.000817	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	4.93e-06	0.000758	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—EP300—systemic lupus erythematosus	4.59e-06	0.000705	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	4.31e-06	0.000663	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PPARG—systemic lupus erythematosus	4.25e-06	0.000653	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—RXRA—systemic lupus erythematosus	3.87e-06	0.000594	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—RXRA—systemic lupus erythematosus	3.87e-06	0.000594	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—ALB—systemic lupus erythematosus	3.82e-06	0.000587	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—NOS3—systemic lupus erythematosus	3.66e-06	0.000562	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	3.59e-06	0.000551	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PPARG—systemic lupus erythematosus	3.53e-06	0.000543	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PTGS2—systemic lupus erythematosus	3.34e-06	0.000514	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—ALB—systemic lupus erythematosus	3.18e-06	0.000488	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—NOS3—systemic lupus erythematosus	3.04e-06	0.000467	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—RXRA—systemic lupus erythematosus	2.98e-06	0.000458	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—EP300—systemic lupus erythematosus	2.78e-06	0.000427	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PTGS2—systemic lupus erythematosus	2.78e-06	0.000427	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PPARG—systemic lupus erythematosus	2.44e-06	0.000375	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PPARG—systemic lupus erythematosus	2.44e-06	0.000375	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—EP300—systemic lupus erythematosus	2.31e-06	0.000355	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—ALB—systemic lupus erythematosus	2.2e-06	0.000337	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—ALB—systemic lupus erythematosus	2.2e-06	0.000337	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—NOS3—systemic lupus erythematosus	2.1e-06	0.000323	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—NOS3—systemic lupus erythematosus	2.1e-06	0.000323	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PTGS2—systemic lupus erythematosus	1.92e-06	0.000295	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PTGS2—systemic lupus erythematosus	1.92e-06	0.000295	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PPARG—systemic lupus erythematosus	1.88e-06	0.000289	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—ALB—systemic lupus erythematosus	1.69e-06	0.00026	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—NOS3—systemic lupus erythematosus	1.62e-06	0.000249	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—EP300—systemic lupus erythematosus	1.6e-06	0.000245	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—EP300—systemic lupus erythematosus	1.6e-06	0.000245	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PTGS2—systemic lupus erythematosus	1.48e-06	0.000228	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—EP300—systemic lupus erythematosus	1.23e-06	0.000189	CbGpPWpGaD
